OncoNano Medicine Presents Positive Final Results from Phase 2 Trial of Pegsitacianine in Podium Presentation…
Read More
OncoNano Medicine Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting…
OncoNano Presents Compelling Data for ONM-501 and a Novel Tumor Specific Delivery Technology at AACR…
OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO)…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced three poster presentations at…
Southlake, TX – January 4, 2023 – OncoNano Medicine, Inc. today announced that its lead clinical…
Clinically validated pH-sensitive nanomedicine platform allows for tumor specific delivery of protein therapeutics and increased…
ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
– Interim Phase 2 results presented at World Molecular Imaging Conference 2022 – – Pegsitacianine…
SOUTHLAKE, Texas – September 19, 2022 – OncoNano Medicine, Inc., a clinical-stage biotechnology company focused…